520 First-line chemotherapy with carboplatin, cisplatin and cyclophosphamide (C.C.C) in advanced ovarian cancer (AOC)
| Autor: | D.Z. Edelmann, S.O. Anteby, V. Barak, Tamar Peretz |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Cisplatin
Cancer Research medicine.medical_specialty Cyclophosphamide business.industry medicine.disease Gastroenterology Carboplatin Surgery chemistry.chemical_compound Regimen Carboplatin/cisplatin Oncology chemistry Planned Dose Internal medicine Toxicity Medicine business Ovarian cancer medicine.drug |
| Zdroj: | European Journal of Cancer. 31:S111 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(95)95774-z |
| Popis: | The combination of C.C.C was delivered to 30 patients with AOC. Of these patients 24 had suboptimally debulked and 6 had optimally debulked tumors. C.C.C regimen was given as follows: Carboplatin 200 mg/m2 d1, Cisplatin 60 mg/m2 d2 and Cyclophosphamide 550 mg/m2 d1, 2 q 4 weeks, for 6 cycles. Of 24 patients with sub-optimally debulked, measurable disease 23 (96%) had a clinical response, including 18 (75%) with clinical complete response (CR), of whom 15 underwent a second look laparotomy. Macroscopic CR was found in 10 (42%) patients of whom 6 (25%) had a pathologic CR. After a median follow-up duration of 16 months median survival is pending. For all 30 patients, grade IV leucopenia was noted in 50% and leucopenic fever in 23% of the patients. Grade IV thrombocytopenia was noted in 20%. No other grade III–IV toxicity was noted. There was no toxic death. 90–100% of planned dose was administered to 87% of pts, while 13% received 80–89% of the planned dose. C.C.C is active and safe in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect